Authorized generics

Prasco Launches Authorized Generic of ZIOPTAN® Ophthalmic Solution

Retrieved on: 
Friday, November 18, 2022
Cerebral edema, Macular edema, Pharmacy, THA, Prasco Laboratories, Risk, Laboratory, Safety, Partnership, Iris, Pigment, Prescription, Lens (anatomy), Multimedia, Patient, Glaucoma, Ocular hypertension, Inflammation, Eyelash, Merck Sharp & Dohme Federal Credit Union, Authorized generics, General of the branch, Generic drug, Pharmaceutical industry, Prasco

MASON, Ohio, Nov. 18, 2022 /PRNewswire/ -- Prasco Laboratories announced today the launch of the Authorized Generic of ZIOPTAN (tafluprost ophthalmic solution) 0.0015%.

Key Points: 
  • MASON, Ohio, Nov. 18, 2022 /PRNewswire/ -- Prasco Laboratories announced today the launch of the Authorized Generic of ZIOPTAN (tafluprost ophthalmic solution) 0.0015%.
  • This is Prasco's first Authorized Generic launch in partnership with Tha Pharma, Inc.
    Prasco's Tafluprost Ophthalmic Solution 0.0015% is therapeutically equivalent to ZIOPTAN, marketed under the Prasco label, and will be widely available in U.S. pharmacies.
  • Tafluprost Ophthalmic Solution 0.0015% is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
  • The most innovative and trusted brand companies rely on Prasco to bring their products to the generic marketplace as Authorized Generics.

Amring Pharmaceuticals Inc. Acquires LYSTEDA®

Retrieved on: 
Wednesday, December 2, 2020
Biotechnology, General Health, Pharmaceutical, Health, Pharmaceuticals policy, Health care, Health, Pharmaceutical industry, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Generic drug, Authorized generics, Pharmaceutical industry in India, Amring Pharmaceuticals Inc., Ferring International Center S.A.

Amring has been marketing the authorized generic version of LYSTEDA in the USA since March 14, 2016.

Key Points: 
  • Amring has been marketing the authorized generic version of LYSTEDA in the USA since March 14, 2016.
  • With the acquisition of LYSTEDA, Amring is further securing its position as a market leader in the treatment of HMB and expands product opportunities in markets outside of the USA, stated Daniel Carbery, President and CEO of Amring.
  • Amring Pharmaceuticals is a privately held pharmaceutical company that provides value brands and niche generics to the market.
  • Amring is uniquely positioned to leverage its partners expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.

Pharmaceutical Manufacturers Establish New Coalition to Raise Awareness of Authorized Generics

Retrieved on: 
Thursday, November 5, 2020
Health sciences, Life sciences, Pharmaceuticals policy, Health care, Authorized generics, Pfizer, Generic drug, Pharmaceutical industry, Greenstone

Washington, DC, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Today, leading manufacturers announced the formation of a coalition that will raise awareness of the important category of Authorized Generic medicines.

Key Points: 
  • Washington, DC, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Today, leading manufacturers announced the formation of a coalition that will raise awareness of the important category of Authorized Generic medicines.
  • We hope this coalition will raise awareness of Authorized Generics as an important option for patients.
  • The Coalition of Authorized Generics will be comprised of pharmaceutical manufacturers, patient advocacy organizations, and other parties who want to raise public awareness of Authorized Generics and seek to remove needless barriers patients face when searching for Authorized Generics.
  • Greenstone provides Authorized Generics (AGs) from Pfizer as well as other manufacturers, in addition to some generic products.

Lannett Launches Authorized Generic of Tirosint® (Levothyroxine Sodium Capsules)

Retrieved on: 
Tuesday, November 3, 2020
Anatomy, Glands, Pharmaceutical industry, Pharmaceuticals policy, Thyroid, Levothyroxine, Authorized generics

Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a share of the profits.

Key Points: 
  • Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a share of the profits.
  • "Currently, we believe we are the sole provider of all 12 currently marketed dosage strengths for generic Levothyroxine Capsules," said Tim Crew, chief executive officer of Lannett.
  • Levothyroxine Sodium Capsules USP is the authorized generic of Tirosint of IBSA Institut Biochimique SA.
  • Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.

2020 Pharmaceutical Drug Patent Database - Active US & International Patents - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 27, 2020
Health, Pharmaceutical, Health sciences, Pharmaceuticals policy, Articles, Health, Patent law, Pharmacy, Drug pricing, Pharmaceutical industry, Chemical patent, Authorized generics, Drug, Generic drug

The "Drug Patent Database Subscription: Pharmaceutical Drugs" database has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Drug Patent Database Subscription: Pharmaceutical Drugs" database has been added to ResearchAndMarkets.com's offering.
  • This subscription for the Pharmaceutical Drugs portion of the database offers information on:
    US & International Patents, including active and expired patents in 134 Countries, regulatory protections and exclusivities;
    Information that anticipates drug entries into the generic market, including Loss-of-Exclusivity Dates, Paragraph IV Challenges, Tentative Approvals, Authorized Generics, and more.
  • The Pharmaceutical Drugs Plan Database helps drug companies make better decisions through the delivery of cutting-edge business intelligence.
  • The Pharmaceutical Drug plan is focused on the interests of small-molecule drug manufacturers, suppliers, distributors, and payers.

Global Cancer Generics Market Size Sales Demand Dominating the Branded Drug Status With US$ 55 Billion Future Opportunity By 2026

Retrieved on: 
Thursday, September 10, 2020
Articles, Health, Life sciences, Pharmaceuticals policy, Generic drug, Public domain, Pharmaceutical industry, Authorized generics, Dr. Reddy's Laboratories

NEW DELHI, Sept. 10, 2020 /PRNewswire/ -- "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, Sept. 10, 2020 /PRNewswire/ -- "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" Report Highlights:
    Global Cancer Generics Market Opportunity: > USD 55 Billion By 2026
    Global Generics Market Growth 2018-2026: > 130%
    Global Cancer Generics Market Growth 2018-2026: 200%
    Comprehensive Insight On Cancer Generics Drugs: 43 Generics
    For Cell Therapy, Gene Therapy, Vaccine, Antibodies, Oncology Market & Clinical Pipeline Reports Visit: https://www.kuickresearch.com/page-Pharmaceutical%20and%20Healthcare.php
    Amid the growth in terms of revenue and size that pharmaceutical market is experiencing, a significant contribution is laid down by the arrival of cancer generic drugs in the market.
  • The market is also responsible for upending the traditional forms of the cancer treatments and the engaged process of pricing about the different cancer therapies available.
  • As per "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" report, it is observed that the convergence that the market has observed from branded cancer drugs to generic cancer drugs is becoming very prominent and fulfilling in terms of trends and opportunities.
  • It is estimated that the growing cancer generics market will provide numerous growth opportunities to the stakeholders as well as the healthcare customers.

Cipla Receives Final Approval for Generic Version of Migranal® (Dihydroergotamine Mesylate Nasal Spray 4mg/mL) With a Competitive Generic Therapy Designation

Retrieved on: 
Thursday, May 21, 2020
Service companies, Articles, GABAA receptor positive allosteric modulators, Lactams, Lysergamides, Pharmaceutical industry, Pharmaceuticals policy, Dihydroergotamine, IMS Health, Authorized generics, Spray, IQVIA

This 180-day CGT exclusivity will not block the commercialization of the existing approvals of Dihydroergotamine Mesylate Nasal Spray, 4 mg/mL.

Key Points: 
  • This 180-day CGT exclusivity will not block the commercialization of the existing approvals of Dihydroergotamine Mesylate Nasal Spray, 4 mg/mL.
  • Cipla's Dihydroergotamine Mesylate Nasal Spray 4mg/mL is AB-rated generic therapeutic equivalent version of Bausch Health US LLC's Migranal .
  • This is Cipla's first ANDA approval for a nasal spray.
  • According to IQVIA (IMS Health), Migranal and its authorized generic equivalents had U.S. sales of approximately $102M for the 12-month period ending March 2020.

Global Cancer Generics Market (2018 to 2026) - Reimbursement Policies & the Coverage Strategies by Country - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 18, 2020
Pharmaceutical, Health, Oncology, Health, Pharmaceuticals policy, Articles, Pharmaceutical industry, Generic drug, Public domain, Pharmaceutical industry in India, Dr. Reddy's Laboratories, Authorized generics

The "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • It is a result of the extensive study conducted by analyzing the global companies for cancer generics.
  • Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" Report Highlights:
    Global Cancer Generics Market Opportunity: > USD 55 Billion By 2026
    Global Generics Market Growth 2018-2026: > 130%
    Global Cancer Generics Market Growth 2018-2026: 200%
    Comprehensive Insight On Cancer Generics Drugs: 43 Generics
    Cancer generics market gets highlighted by the minimal efforts drug makers have to put and the maximum advantages that the patients will receive.
  • The market of cancer generics is also escalating by the fact that the number of pharmaceuticals players interested in manufacturing generic drugs have been increasing.

Endo Begins Shipment of Authorized Generic Version of Carafate® (sucralfate) Oral Suspension in the United States

Retrieved on: 
Monday, January 27, 2020
Pharmaceutical industry, Pharmaceuticals policy, Health, Mergers and acquisitions, Articles, Endo International plc, Allergan, Authorized generics, Sucralfate, Generic drug

DUBLIN, Jan. 27, 2020 /PRNewswire/ --Endo International plc(NASDAQ: ENDP) today announced that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Allergan's Carafate (sucralfate) oral suspension 1gm/10 mL.

Key Points: 
  • DUBLIN, Jan. 27, 2020 /PRNewswire/ --Endo International plc(NASDAQ: ENDP) today announced that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Allergan's Carafate (sucralfate) oral suspension 1gm/10 mL.
  • "Par is proud to partner with Allergan to bring the authorized generic of Carafate to patients," saidDomenic Ciarico, Executive Vice President & Chief Commercial Officer, Sterile & Generics atEndo.
  • "We are pleased to add this product to our portfolio and continue Par's tradition of being a reliable, quality supplier."
  • According to IQVIA data, U.S market annual sales for the 12 months ended November 30, 2019, for sucralfate oral suspension was estimated to be approximately $285 million.

Endo Begins Shipment of Authorized Generic Version of Carafate® (sucralfate) Oral Suspension in the United States

Retrieved on: 
Monday, January 27, 2020
Pharmaceutical industry, Pharmaceuticals policy, Health, Mergers and acquisitions, Articles, Endo International plc, Allergan, Authorized generics, Sucralfate, Generic drug

DUBLIN, Jan. 27, 2020 /PRNewswire/ --Endo International plc(NASDAQ: ENDP) today announced that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Allergan's Carafate (sucralfate) oral suspension 1gm/10 mL.

Key Points: 
  • DUBLIN, Jan. 27, 2020 /PRNewswire/ --Endo International plc(NASDAQ: ENDP) today announced that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Allergan's Carafate (sucralfate) oral suspension 1gm/10 mL.
  • "Par is proud to partner with Allergan to bring the authorized generic of Carafate to patients," saidDomenic Ciarico, Executive Vice President & Chief Commercial Officer, Sterile & Generics atEndo.
  • "We are pleased to add this product to our portfolio and continue Par's tradition of being a reliable, quality supplier."
  • According to IQVIA data, U.S market annual sales for the 12 months ended November 30, 2019, for sucralfate oral suspension was estimated to be approximately $285 million.